Teladoc Health delivered Q4 2025 revenue of $642.3 million, which was flat year-over-year, while adjusted EBITDA grew 12% to $83.8 million. The company saw a significant narrowing of its net loss compared to the prior year, driven by growth in the Integrated Care segment and international markets, despite a decline in BetterHelp revenue.

Teladoc Health experienced a challenging third quarter in 2025, with consolidated revenues decreasing by 2% to $626.4 million and adjusted EBITDA falling by 16% to $69.9 million. The company reported a net loss of $49.5 million, or $0.28 per share, which included a non-cash goodwill impairment charge.

Teladoc Health's second quarter of 2025 saw a 2% decrease in consolidated revenue to $631.9 million, with adjusted EBITDA also declining by 23% to $69.3 million. Despite these decreases, the company significantly reduced its net loss to $32.7 million from $837.7 million in the prior year, primarily due to the absence of a large goodwill impairment charge. Integrated Care segment revenue grew, while BetterHelp revenue declined.

Teladoc Health reported a decrease in revenue and adjusted EBITDA in the first quarter of 2025 compared to the prior year. Revenue decreased 3% to $629.4 million, and adjusted EBITDA decreased 8% to $58.1 million. The company also reported a net loss of $93.0 million. Integrated Care segment revenue increased, while BetterHelp segment revenue decreased. The company completed the acquisition of UpLift Health Technologies during the quarter.

Teladoc Health concluded 2024 with a solid performance in Q4, despite a slight revenue decrease. Integrated Care showed growth and margin expansion, while BetterHelp faced challenges in a difficult operating environment. The company is focused on execution and cost structure improvements for 2025.

Teladoc Health reported Q3 2024 revenue of $640.5 million, a 3% decrease year-over-year. Net loss was $33.3 million, or $0.19 per share. The Integrated Care segment saw revenue increase by 2%, while the BetterHelp segment experienced a 10% decrease.

Teladoc Health reported a 2% year-over-year decrease in revenue to $642.4 million for Q2 2024. The company experienced a net loss of $837.7 million, which includes a goodwill impairment charge of $790.0 million. While the Integrated Care segment performed well, the BetterHelp segment faced continued headwinds.

Teladoc Health reported a 3% year-over-year revenue increase to $646.1 million for Q1 2024. The company's net loss was $81.9 million, or $0.49 per share, while adjusted EBITDA increased by 20% year-over-year to $63.1 million.

Teladoc Health reported a 4% increase in revenue for Q4 2023, reaching $660.5 million. The net loss was $28.9 million, a significant improvement from the $3,810.1 million loss in Q4 2022. Adjusted EBITDA increased by 22% to $114.4 million. The company provided financial guidance for Q1 2024 and the full year 2024.

Teladoc Health's Q3 2023 earnings reflect a solid financial performance with revenue reaching $660.2 million, an 8% increase year-over-year. The company also reported strong operating cash flow and made progress in expanding its virtual care offerings.

Teladoc Health reported a 10% year-over-year increase in revenue, reaching $652.4 million for the second quarter of 2023. The company's operating cash flow was $101.2 million, with a free cash flow of $64.6 million. Net loss was $65.2 million, or $0.40 per share, while adjusted EBITDA increased by 54% to $72.2 million.

Teladoc Health's first quarter 2023 showed an 11% increase in revenue year-over-year, reaching $629.2 million. The company's net loss was $69.2 million, or $0.42 per share. The company saw growth in both U.S. and International revenues, as well as in the Integrated Care and BetterHelp segments.

Teladoc Health reported a 15% increase in revenue for Q4 2022, reaching $637.7 million. However, the company experienced a net loss of $3,810.1 million, or ($23.49) per share, primarily due to non-cash goodwill impairment charges of $3.8 billion.

Teladoc Health reported a 17% increase in revenue, reaching $611.4 million. The net loss was $73.5 million, or $0.45 per share. Adjusted EBITDA totaled $51.2 million. Cash flow from operating activities was $63.0 million for the quarter.

Teladoc Health's Q2 2022 earnings report showed an 18% increase in revenue year-over-year, reaching $592.4 million. However, the company reported a significant net loss of $3,101.5 million, or $19.22 per share, primarily due to a non-cash goodwill impairment charge of $3.0 billion.

Teladoc Health reported a 25% increase in revenue to $565.4 million for Q1 2022. However, the company experienced a significant net loss of $6.67 billion, or $41.58 per share, primarily due to a $6.6 billion non-cash goodwill impairment charge. The full-year guidance for 2022 has been revised to $2.4 - $2.5 billion in revenue, a net loss per share of ($43.50) - ($43.00), and adjusted EBITDA of $240 - $265 million.

Teladoc Health reported a 45% year-over-year increase in fourth-quarter revenue, reaching $554.2 million. Total visits also increased by 41% to 4.4 million. The company's full-year revenue grew by 86% to $2,032.7 million.

Teladoc Health reported strong third-quarter results with revenue growing 81% year-over-year to $522 million. Total third quarter visits topped 3.9 million, a 37% increase from Q3 2020. The company updated its 2021 revenue outlook to $2,015 million to $2,025 million.

Teladoc Health reported a strong second quarter with revenue growing 109% year-over-year to $503 million. The company also raised its full-year revenue guidance to $2.000 million to $2.025 million. Total visits increased by 28% compared to the same quarter last year, reaching 3.5 million.

Teladoc Health reported a strong first quarter with revenue increasing by 151% year-over-year to $453.7 million and total visits increasing by 56% to 3.2 million. The company is making progress on its integration efforts, including the launch of Medical Group referrals into chronic care management programs and a new whole-person care contract. The company raised its full-year guidance.

Teladoc Health's Q4 2020 results showed significant growth, with revenue increasing by 145% year-over-year to $383.3 million and total visits up by 139% to 3.0 million. The company transformed to define a new category of whole-person virtual care. However, the company reported a net loss of $(394.0) million for the quarter, which included acquisition and integration-related costs and accelerated stock-based awards expense related to the merger with Livongo.

Teladoc Health reported a 109% year-over-year increase in Q3 revenue, reaching $288.8 million. Total visits also saw a significant increase of 206% to 2.8 million. The company issued Q4 guidance and raised full-year expectations, highlighting new client partnerships and sustainable growth.

Teladoc Health reported an 85% year-over-year revenue growth to $241.0 million for Q2 2020, with total visits increasing by 203% to 2.8 million. The company issued Q3 guidance, raised full-year expectations, and provided a preliminary 2021 revenue growth outlook.

Teladoc Health reported a 41% year-over-year revenue increase to $180.8 million for Q1 2020. Total visits increased by 92% to 2.0 million. The company issued Q2 2020 guidance and updated full-year expectations.

Teladoc Health reported strong Q4 2019 results, with revenue increasing by 27% year-over-year to $156.5 million and total visits increasing by 44% to 1.2 million. The company's diversified growth strategies are driving strong growth across its channels.